KR102745965B1 - 간질, 중독 및 간세포암종의 치료를 위한 gaba 아미노트랜스페라제 불활성화제들로서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산, 및 관련된 화합물들 - Google Patents
간질, 중독 및 간세포암종의 치료를 위한 gaba 아미노트랜스페라제 불활성화제들로서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산, 및 관련된 화합물들 Download PDFInfo
- Publication number
- KR102745965B1 KR102745965B1 KR1020187013228A KR20187013228A KR102745965B1 KR 102745965 B1 KR102745965 B1 KR 102745965B1 KR 1020187013228 A KR1020187013228 A KR 1020187013228A KR 20187013228 A KR20187013228 A KR 20187013228A KR 102745965 B1 KR102745965 B1 KR 102745965B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- pharmaceutical composition
- article
- salt
- delete delete
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
-
- Y10S514/81—
-
- Y10S514/909—
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239330P | 2015-10-09 | 2015-10-09 | |
| US62/239,330 | 2015-10-09 | ||
| PCT/US2016/056245 WO2017062942A2 (en) | 2015-10-09 | 2016-10-10 | (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180052782A KR20180052782A (ko) | 2018-05-18 |
| KR102745965B1 true KR102745965B1 (ko) | 2024-12-20 |
Family
ID=58488679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187013228A Active KR102745965B1 (ko) | 2015-10-09 | 2016-10-10 | 간질, 중독 및 간세포암종의 치료를 위한 gaba 아미노트랜스페라제 불활성화제들로서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산, 및 관련된 화합물들 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9670141B2 (https=) |
| EP (1) | EP3341355B1 (https=) |
| JP (1) | JP6841821B2 (https=) |
| KR (1) | KR102745965B1 (https=) |
| CN (1) | CN108137484B (https=) |
| AU (1) | AU2016334396B2 (https=) |
| BR (1) | BR112018007026B1 (https=) |
| CA (1) | CA3001330A1 (https=) |
| CL (1) | CL2018000914A1 (https=) |
| CO (1) | CO2018003828A2 (https=) |
| DK (1) | DK3341355T3 (https=) |
| ES (1) | ES2825349T3 (https=) |
| HU (1) | HUE053429T2 (https=) |
| IL (1) | IL258516A (https=) |
| LT (1) | LT3341355T (https=) |
| MX (1) | MX380592B (https=) |
| PE (1) | PE20190349A1 (https=) |
| PL (1) | PL3341355T3 (https=) |
| PT (1) | PT3341355T (https=) |
| WO (1) | WO2017062942A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59111B1 (sr) | 2014-08-21 | 2019-09-30 | Boehringer Ingelheim Int | Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori |
| JP6841821B2 (ja) * | 2015-10-09 | 2021-03-10 | ノースウェスタン ユニバーシティ | てんかん、嗜癖および肝細胞癌の処置のためのｇａｂａアミノトランスフェラーゼ不活性化剤としての（ｓ）−３−アミノ−４−（ジフルオロメチレニル）シクロペント−１−エン−１−カルボン酸および関連化合物 |
| KR20240158360A (ko) | 2015-10-09 | 2024-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체 |
| EP4692048A3 (en) * | 2017-02-08 | 2026-04-01 | Ovid Therapeutics Inc. | Methods of treating cdkl5 disorders with the compound ov329 |
| US11771671B2 (en) | 2018-02-08 | 2023-10-03 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| KR20250167147A (ko) | 2018-02-08 | 2025-11-28 | 오비드 테라퓨틱스 인크. | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
| JP2021519753A (ja) * | 2018-03-29 | 2021-08-12 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 眼障害の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 |
| US10822301B2 (en) | 2018-04-12 | 2020-11-03 | Northwestern University | 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase |
| MX2020012691A (es) * | 2018-05-25 | 2021-02-15 | Univ Northwestern | Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico. |
| CA3102786A1 (en) * | 2018-06-07 | 2019-12-12 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigab atrin in the treatment of developmental disorders |
| US11203596B2 (en) | 2019-02-25 | 2021-12-21 | Northwestern University | Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity |
| US11078153B2 (en) | 2019-04-03 | 2021-08-03 | Northwestern University | 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase |
| CN110935495B (zh) * | 2019-11-29 | 2021-02-23 | 中国科学院电子学研究所 | Gaba和电生理微纳同步传感检测芯片及其制备方法 |
| US11993569B2 (en) | 2020-01-23 | 2024-05-28 | Northwestern University | 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases |
| WO2022187523A1 (en) * | 2021-03-03 | 2022-09-09 | Northwestern University | (s)-3-amino-4,4-dihalocyclopent-1-enecarboxylic acid as selective inactivators of human ornithine aminotransferase |
| EP4482478A4 (en) * | 2022-02-27 | 2026-03-04 | Univ Northwestern | (3S,4R)-3-AMINO-4-(DIFLUOROMETHYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS USED AS SELECTIVE ORNITHIN AMINOTRANSFERASE ACTIVATORS |
| KR20250034134A (ko) * | 2022-07-06 | 2025-03-10 | 오비드 테라퓨틱스 인크. | 암 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸렌일)사이클로펜트-1-엔-1-카르복실산의 사용 |
| US20240285563A1 (en) * | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis |
| EP4648757A4 (en) * | 2023-02-17 | 2026-01-07 | Ovid Therapeutics Inc | USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID FOR THE TREATMENT OF GASTROINTESTINAL TRACT DISORDERS AND AS AN IMMUNOMODULATING AGENT |
| JP2026506097A (ja) * | 2023-02-17 | 2026-02-20 | オービッド・セラピューティクス・インコーポレイテッド | 多発性硬化症の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペント－１－エン－１－カルボン酸の使用 |
| US20240285565A1 (en) * | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008023364A1 (en) | 2006-08-21 | 2008-02-28 | Hadasit Medical Research Services & Development Ltd. | Inhibition of ornithine aminotransferase for the treatment of proliferative disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| TWI468403B (zh) * | 2011-08-30 | 2015-01-11 | Gilead Sciences Inc | 用於治療成癮之ａｌｄｈ－２抑制劑 |
| JP6841821B2 (ja) * | 2015-10-09 | 2021-03-10 | ノースウェスタン ユニバーシティ | てんかん、嗜癖および肝細胞癌の処置のためのｇａｂａアミノトランスフェラーゼ不活性化剤としての（ｓ）−３−アミノ−４−（ジフルオロメチレニル）シクロペント−１−エン−１−カルボン酸および関連化合物 |
-
2016
- 2016-10-10 JP JP2018517734A patent/JP6841821B2/ja active Active
- 2016-10-10 ES ES16854531T patent/ES2825349T3/es active Active
- 2016-10-10 PL PL16854531T patent/PL3341355T3/pl unknown
- 2016-10-10 HU HUE16854531A patent/HUE053429T2/hu unknown
- 2016-10-10 US US15/289,480 patent/US9670141B2/en active Active
- 2016-10-10 PT PT168545317T patent/PT3341355T/pt unknown
- 2016-10-10 WO PCT/US2016/056245 patent/WO2017062942A2/en not_active Ceased
- 2016-10-10 AU AU2016334396A patent/AU2016334396B2/en active Active
- 2016-10-10 DK DK16854531.7T patent/DK3341355T3/da active
- 2016-10-10 CN CN201680059069.9A patent/CN108137484B/zh active Active
- 2016-10-10 CA CA3001330A patent/CA3001330A1/en active Pending
- 2016-10-10 LT LTEP16854531.7T patent/LT3341355T/lt unknown
- 2016-10-10 KR KR1020187013228A patent/KR102745965B1/ko active Active
- 2016-10-10 BR BR112018007026-2A patent/BR112018007026B1/pt active IP Right Grant
- 2016-10-10 EP EP16854531.7A patent/EP3341355B1/en active Active
- 2016-10-10 PE PE2018000517A patent/PE20190349A1/es unknown
- 2016-10-10 MX MX2018004302A patent/MX380592B/es unknown
-
2017
- 2017-05-04 US US15/586,730 patent/US9993449B2/en active Active
-
2018
- 2018-04-05 IL IL258516A patent/IL258516A/en active IP Right Grant
- 2018-04-09 CL CL2018000914A patent/CL2018000914A1/es unknown
- 2018-04-10 CO CONC2018/0003828A patent/CO2018003828A2/es unknown
- 2018-05-29 US US15/991,323 patent/US20180271816A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008023364A1 (en) | 2006-08-21 | 2008-02-28 | Hadasit Medical Research Services & Development Ltd. | Inhibition of ornithine aminotransferase for the treatment of proliferative disorders |
Non-Patent Citations (1)
| Title |
|---|
| Journal of Medicinal Chemistry, 2006, 49(25), 7404-7412. |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102745965B1 (ko) | 간질, 중독 및 간세포암종의 치료를 위한 gaba 아미노트랜스페라제 불활성화제들로서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산, 및 관련된 화합물들 | |
| Silverman | Design and mechanism of GABA aminotransferase inactivators. Treatments for epilepsies and addictions | |
| Conti et al. | Drug discovery targeting amino acid racemases | |
| Juncosa et al. | Design and mechanism of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid, a highly potent γ-aminobutyric acid aminotransferase inactivator for the treatment of addiction | |
| Schousboe et al. | GABA: homeostatic and pharmacological aspects | |
| Yogeeswari et al. | The GABA shunt: an attractive and potential therapeutic target in the treatment of epileptic disorders | |
| Ilies et al. | Binding of α, α-disubstituted amino acids to arginase suggests new avenues for inhibitor design | |
| Zhu et al. | A remarkable difference that one fluorine atom confers on the mechanisms of inactivation of human ornithine aminotransferase by two cyclohexene analogues of γ-aminobutyric acid | |
| Yuan et al. | New substrates and inhibitors of γ-aminobutyric acid aminotransferase containing bioisosteres of the carboxylic acid group: Design, synthesis, and biological activity | |
| WO2020206234A1 (en) | 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase | |
| US12492164B2 (en) | Fluorine substituted cyclohexene analogues of gamma-aminobutyric acid (GABA) | |
| Hallen et al. | Imine reductases: a comparison of glutamate dehydrogenase to ketimine reductases in the brain | |
| HK1253002B (zh) | 作为用於治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物 | |
| Wawro et al. | Enantiomers of 2-methylglutamate and 2-methylglutamine selectively impact mouse brain metabolism and behavior | |
| Das | A Metabolic Approach to Investigate the Role of Amino Acids in Brain | |
| CA3237375A1 (en) | Cysteamine and/or cystamine prodrugs | |
| Yuan | Novel substrates and inhibitors of γ-aminobutyric acid aminotransferase (GABA-AT): Design, synthesis, biological activities, and mechanistic studies | |
| WO2023164715A2 (en) | (3s,4r)-3-amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic acid and related compounds as selective inactivators of ornithine aminotransferase | |
| CA3212755A1 (en) | Enantiomer selective action on neurotransmission | |
| Wang | Mechanism-based design, syntheses, and evaluation of potential inhibitors of γ-aminobutyric acid aminotransferase (GABA-AT) | |
| Beio | An Integrated Study of PLP-Dependent Enzyme Mechanisms Through Targeted Mutagenesis, Inhibitor Design and Kinetic Evaluation | |
| Pan | Design, syntheses and mechanistic studies of γ-aminobutyric acid aminotransferase inhibitors | |
| Bey | AS AN APPROACH TO DRUG DESIGN | |
| JPH11183696A (ja) | 標識α−ハロゲノアルキル芳香族アミノ酸およびこれを用いる標識試薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180509 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20211008 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230918 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240208 Patent event code: PE09021S01D |
|
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240925 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20241218 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20241218 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |